POLAPREZINC

First approved in 2019

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C9H12N4O3.Zn
Molecular Weight	289.626
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Zn++].NCCC(=O)[N-][C@@H](CC1=CN=CN1)C([O-])=O

InChI

InChIKey=IGXZLYMCFZHNKW-FJXQXJEOSA-L

InChI=1S/C9H14N4O3.Zn/c10-2-1-8(14)13-7(9(15)16)3-6-4-11-5-12-6;/h4-5,7H,1-3,10H2,(H3,11,12,13,14,15,16);/q;+2/p-2/t7-;/m0./s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20104529 | https://www.ncbi.nlm.nih.gov/pubmed/10102958 | https://adisinsight.springer.com/drugs/800000612 | https://www.drugfuture.com/chemdata/polaprezinc.html

Polaprezinc is a zinc-containing molecule and used for the therapy of gastric ulcer. It has been reported that this compound inhibits the induction of TNF-a as well as cellular signaling of TNF-a. Polaprezinc has been shown to exert an anti-oxidant property in a tube experiment and accelerate the healing of gastric ulcer in humans. Polaprezinc inhibited EtOH-induced cytochrome c reduction. Protection by polaprezinc was microscopically associated with the prevention of monolayer disruption. In an animal model of chemotherapy-induced oral mucositis polaprezinc improves the recovery from 5-fluorouracil–induced oral mucositis in hamsters. Polaprezinc ameliorates mucosal ulceration in acetic acid-induced experimental oral mucositis in hamsters. Polaprezinc is potentially useful for prevention of oral mucositis and improvement of quality of life without reducing the tumor response. Polaprezinc is in phase II clinical trial for the treatment of taste disorders.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Heat shock 70 kDa protein 1 Target ID: P34934 Gene ID: NA Gene Symbol: NA Target Organism: Sus scrofa (Pig) Sources: https://www.ncbi.nlm.nih.gov/pubmed/23687308	Inhibitor 8297	33.08 µM [IC50]
Vascular endothelial growth factor receptor 1 41 Target ID: CHEMBL1868 Sources: https://www.drugbank.ca/drugs/DB09221 \| https://www.ncbi.nlm.nih.gov/pubmed/23743168	Agonist 2678
Platelet-derived growth factor receptor beta 56 Target ID: CHEMBL1913 Sources: https://www.drugbank.ca/drugs/DB09221 \| https://www.ncbi.nlm.nih.gov/pubmed/23743168	Agonist 2678
Tumor necrosis factor 6 Target ID: P01375 Gene ID: 7124.0 Gene Symbol: TNF Target Organism: Homo sapiens (Human) Sources: https://www.drugbank.ca/drugs/DB09221 \| https://www.ncbi.nlm.nih.gov/pubmed/23743168	Inhibitor 8297

PubMed

Title	Date	PubMed
Polaprezinc combined with clarithromycin-based triple therapy for Helicobacter pylori-associated gastritis: A prospective, multicenter, randomized clinical trial.	2017	28407007
Oral Administration of Polaprezinc Attenuates Fluorouracil-induced Intestinal Mucositis in a Mouse Model.	2017 Dec	28667794
Antioxidant, Anti-inflammatory, and Genomic Stability Enhancement Effects of Zinc l-carnosine: A Potential Cancer Chemopreventive Agent?	2017 Feb-Mar	28094570
Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy.	2017 Jul 31	28759701
Polaprezinc inhibits liver fibrosis and proliferation in hepatocellular carcinoma.	2017 Oct	28849143
Zinc L-carnosine suppresses inflammatory responses in lipopolysaccharide-induced RAW 264.7 murine macrophages cell line via activation of Nrf2/HO-1 signaling pathway.	2017 Oct	28697633
Utility of polaprezinc in reducing toxicities during radiotherapy: a literature review.	2018 Aug	30074413
Prophylactic Effect of Polaprezinc, a Zinc-L-carnosine, Against Chemotherapy-induced Oral Mucositis in Pediatric Patients Undergoing Autologous Stem Cell Transplantation.	2018 Aug	30061237
Zinc, Carnosine, and Neurodegenerative Diseases.	2018 Jan 29	29382141
Effects of polaprezinc on gastric mucosal damage and neurotransmitters in a rat model of chemotherapy-induced vomiting.	2018 Jun	29756515
Insufficient evidence for interventions to prevent dry mouth and salivary gland dysfunction post head and neck radiotherapy.	2018 Mar 23	29568026
Improvement of Dysgeusia by Polaprezinc, a Zinc-L-carnosine, in Outpatients Receiving Cancer Chemotherapy.	2018 Nov	30396959
Risk of post-stroke pneumonia with proton pump inhibitors, H2 receptor antagonists and mucoprotective agents: A retrospective nationwide cohort study.	2019	31067267
Biological, thermal and mechanical characterization of modified glass ionomer cements: The role of nanohydroxyapatite, ciprofloxacin and zinc l-carnosine.	2019 Jan 1	30423762
Protective effect of polaprezinc on acute gastric mucosal injury in rats.	2019 Jan 28	30837398
Protective effect of polaprezinc on cadmium-induced injury of lung epithelium.	2019 Jul 17	31236550
Beneficial effect of polaprezinc on cardiac function post-myocardial infarction: A prospective and randomized clinical trial.	2019 Mar	30855449

Patents

Name

Type

Language

POLAPREZINC

Official Name

English

Z-103

Code

English

L-HISTIDINE, N-.BETA.-ALANYL-, ZINC COMPLEX

Common Name

English

POLAPREZINC [MI]

Common Name

English

.BETA.-ALANYL-L-HISTIDINATO ZINC

Common Name

English

POLAPREZINC [MART.]

Common Name

English

Z 103

Code

English

ZINC L-CARNOSINE

Common Name

English

polaprezinc [INN]

Common Name

English

ZINC, (.BETA.-ALANYL-.KAPPA.N-L-HISTIDINATO(2-)-.KAPPA.N,.KAPPA.O)-

Common Name

English

PROMAC

Common Name

English

ZINC CARNOSINE

Common Name

English

Polaprezinc [WHO-DD]

Common Name

English

POLAPREZINC [JAN]

Common Name

English

ZINC, (N-.BETA.-ALANYL-L-HISTIDINATO(2-)-N,NN,O.ALPHA.)-

Common Name

English

Classification Tree Code System Code

DSLD

137 (Number of products:9660)